These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 9614013)

  • 21. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxyurea marketed for sickle cell anemia.
    Am J Health Syst Pharm; 1998 May; 55(9):875. PubMed ID: 9588244
    [No Abstract]   [Full Text] [Related]  

  • 23. Sickle cell patients find a brand New World.
    Noonan SS
    N J Med; 1999 Aug; 96(8):23-5. PubMed ID: 10457727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
    Zahr RS; Hankins JS; Kang G; Li C; Wang WC; Lebensburger J; Estepp JH
    Am J Hematol; 2019 Jan; 94(1):E27-E29. PubMed ID: 30359463
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term hydroxyurea treatment in young sickle cell patients.
    Maier-Redelsperger M; Labie D; Elion J
    Curr Opin Hematol; 1999 Mar; 6(2):115-20. PubMed ID: 10088642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea for sickle cell anemia.
    Naina HV; Harris S
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
    [No Abstract]   [Full Text] [Related]  

  • 27. Hydroxyurea use among children with sickle cell anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxyurea for Sickle Cell Disease: Now Is the Time!
    Strouse JJ
    South Med J; 2016 Sep; 109(9):535-7. PubMed ID: 27598356
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-term use of hydroxyurea for sickle cell anemia.
    Lee DA; Mueller BU
    JAMA; 2003 Aug; 290(6):753-4; author reply 754. PubMed ID: 12915425
    [No Abstract]   [Full Text] [Related]  

  • 30. Hydroxyurea and sickle cell disease: a chance for every patient.
    Weiner DL; Brugnara C
    JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739
    [No Abstract]   [Full Text] [Related]  

  • 31. Sickle cell paths converge on hydroxyurea.
    Platt OS
    Nat Med; 1995 Apr; 1(4):307-8. PubMed ID: 7585059
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment adherence in patients with sickle cell anemia.
    Drotar D
    J Pediatr; 2010 Mar; 156(3):350-1. PubMed ID: 20056235
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment with hydroxyurea has revolutionized the evolution of sickle cell disease ].
    Bartolucci P; de Montalembert M
    Rev Prat; 2014 Oct; 64(8):1127-8. PubMed ID: 25510141
    [No Abstract]   [Full Text] [Related]  

  • 34. Experts urge wider use of hydroxyurea for sickle cell disease.
    Traynor K
    Am J Health Syst Pharm; 2008 Apr; 65(7):592-3. PubMed ID: 18359960
    [No Abstract]   [Full Text] [Related]  

  • 35. Medical Neglect by Underprescription and Underutilization of Hydroxyurea in Children with Sickle Cell Disease.
    Rana S
    South Med J; 2016 Sep; 109(9):503-5. PubMed ID: 27598349
    [No Abstract]   [Full Text] [Related]  

  • 36. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 37. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M; Mizuno T; Vinks AA
    Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
    Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
    Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.